@misc{oai:repo.qst.go.jp:00072921,
 author = {Takakusagi, Yoichi and Takakusagi, Kaori and Inoue, Kaori and Ichikawa, Kazuhiro and 高草木 洋一 and 高草木 香織},
 month = {Sep},
 note = {Hyperpolarized [1-13C]pyruvate magnetic resonance spectroscopic imaging (MRSI) is a promising technique that allows noninvasive assessment of pyruvate conversion to lactate, which is significantly higher in the solid tumors [1]. First-in-human study for metabolic imaging of prostate cancer is ongoing [2]. Very recently, we have reported the use of this approach for noninvasive assessment of therapeutic response to LDH inhibitor for mice-bearing tumor xenografts of PSA-negative human prostate carcinoma (DU145, PC-3) [3]. In the present study, hyperpolarized [1-13C]pyruvate MRS was employed to detect metabolic alterations in the early phase of three-dimensional (3D) organization of these cells. 
\n[1] Day S.E. et al. Nat. Med. 13, 1382 (2007)
[2] Nelson S.J. et al. Sci. Transl. Med. 5, 198ra108 (2013)
[3] Scroggins B.T. et al. Clin. Cancer Res. 24, 3137 (2018), HYP18 −An International Conference on Nuclear Hyperpolarization},
 title = {Hyperpolarized [1-13C]pyruvate MRS reveals increased aerobic glycolysis in the ultra-early phase of PSA-negative prostate carcinogenesis},
 year = {2018}
}